faqs.org » Abstracts Index » Abstracts » Health

Reply to 'Arsenic patent keeps drug for rare cancer out of reach for many'

Article Abstract:

The author refutes the central theme of the article 'Arsenic patent keeps drug for rare cancer out of reach for many'. He asserts that the nondisclosure of the medicinal formulation of the drug for acute promyelocytic leukemia (APL) in the 1990s led to the manufacture of the safe, though expensive, U.S.-patented drug.

All Other Basic Inorganic Chemical Manufacturing, Patents & copyrights, Industrial inorganic chemicals, not elsewhere classified, Arsenic & Compounds, Health aspects, Drug therapy, Intellectual property, Arsenic compounds, Leukemia

---

Too many vessels? Not enough? The wrong kind? The VEGF debate continues

Article Abstract:

Research presented concerns the safety of vascular endothelial growth factor (VEGF) used to treat atherosclerosis, focusing on the adverse effects that include atherosclerotic plaque development. Research from clinical trials of angiogenic agents provides information on how VEGF induces plaque progression.

Complications and side effects, Development and progression, Vascular endothelial growth factor, Atherosclerosis

---

Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis

Article Abstract:

Tumor lymphangiogenesis has been highly correlated with the spread of lung and lymph node metastases. This finding establishes the biological significance of intratumoral lymphangiogenesis in breast cancer and identifies how VEGF-C molecularly links lymphangiogenesis with metastasis.

World, Research, Genetic aspects, Breast cancer, Metastasis, Cancer metastasis, Lymphatic diseases

Some parts © 2012 Advameg, Inc.